mitoxantrone + etoposide + gemtuzumab ozogamicin for Acute Myeloid Leukemia

"Clinicaltrials.gov cites that this investigation is actively recruiting individuals to join its trial, which was first announced on February 28th 2019 and edited most recently on February 9th 2022."

"The safety of the combination treatment mitoxantrone + etoposide + gemtuzumab ozogamicin has been assessed as a 2, based on Phase 2 trial data that suggest some degree of safety but do not indicate efficacy."

"This trial is open to 53 applicants aged 18-75 with acute myeloid leukemia or myelodysplastic syndrome that persists after treatment. Eligible patients must be able to comprehend and grant written consent, have an Eastern Cooperative Oncology Group Performance Status of 0-2, a creatinine clearance of at least 30 mL/min, AST and ALT levels no higher than two times the upper normal limit, total bilirubin not exceeding twice the upper normal limit, and CD33 expression detected in over thirty percent of leukemic blasts on the bone marrow sample. Pancytopenia resulting from disease progression"

"Currently, 366 clinical trials are being conducted on the combination of mitoxantrone + etoposide + gemtuzumab ozogamicin. Out of these studies, 100 have developed to Phase 3 tests. The majority of such experiments take place in New york City; however there exists an additional 16368 sites across the globe running corresponding investigations."

"This clinical trial is open to any patient aged between 18 and 75 years old. Furthermore, there are 597 trials for those under the legal age of consent and 1470 for individuals over 65."

"Mitoxantrone + etoposide + gemtuzumab ozogamicin is a commonly employed therapeutic regimen for treating small cell lung cancer and also has applications in the treatment of lymphoma, Hodgkin's disease, metastatic thymic cancer, acute myelocytic leukemia."

"Yes, the clinicaltrials.gov database indicates that this study is in search of participants at present. The first posting was on February 28th 2019 and it has been modified as recently as February 9th 2022; 53 individuals are needed from one particular site to complete the trial."